X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (184) 184
male (123) 123
adult (119) 119
female (119) 119
infectious diseases (110) 110
hiv infections - drug therapy (81) 81
middle aged (80) 80
index medicus (65) 65
immunology (60) 60
hiv (51) 51
treatment outcome (44) 44
anti-hiv agents - therapeutic use (39) 39
hiv infections - complications (39) 39
hiv infections - virology (39) 39
virology (39) 39
antiretroviral therapy, highly active (38) 38
microbiology (38) 38
drug therapy, combination (37) 37
aged (36) 36
risk factors (36) 36
cohort studies (35) 35
viral load (35) 35
cd4 lymphocyte count (34) 34
italy (32) 32
prospective studies (31) 31
genotype (29) 29
hiv-1 - drug effects (28) 28
antiviral agents - therapeutic use (25) 25
pharmacology & pharmacy (25) 25
antiretroviral therapy (24) 24
human-immunodeficiency-virus (24) 24
aids (23) 23
hiv infection (21) 21
hiv infections - immunology (21) 21
italy - epidemiology (21) 21
hepatitis c, chronic - drug therapy (19) 19
adolescent (18) 18
diagnosis (18) 18
research (18) 18
therapy (18) 18
hiv-1 (17) 17
hiv-1 - genetics (17) 17
interferon-alpha - therapeutic use (17) 17
prevalence (17) 17
protease inhibitors (17) 17
ribavirin - therapeutic use (17) 17
rna, viral - blood (17) 17
care and treatment (16) 16
drug therapy (16) 16
gastroenterology & hepatology (16) 16
infection (16) 16
retrospective studies (16) 16
health aspects (15) 15
hepatitis c - complications (15) 15
public, environmental & occupational health (15) 15
young adult (15) 15
active antiretroviral therapy (14) 14
anti-hiv agents - administration & dosage (14) 14
disease (14) 14
hepacivirus - genetics (14) 14
highly active antiretroviral therapy (14) 14
human immunodeficiency virus--hiv (14) 14
management (14) 14
mortality (14) 14
reverse transcriptase inhibitors - therapeutic use (14) 14
epidemiology (13) 13
hiv patients (13) 13
infected patients (13) 13
polyethylene glycols - therapeutic use (13) 13
disease progression (12) 12
hepatitis (12) 12
hepatitis c, chronic - complications (12) 12
hiv infections - epidemiology (12) 12
human immunodeficiency virus (12) 12
mutation (12) 12
anti-bacterial agents - therapeutic use (11) 11
anti-hiv agents - adverse effects (11) 11
efficacy (11) 11
hcv (11) 11
infections (11) 11
medicine, general & internal (11) 11
ribavirin (11) 11
risk (11) 11
risk-factors (11) 11
tenofovir (11) 11
time factors (11) 11
child (10) 10
gastroenterology and hepatology (10) 10
hepatitis c virus (10) 10
hiv infections - blood (10) 10
hiv protease inhibitors - therapeutic use (10) 10
hiv-infected patients (10) 10
infectious disease (10) 10
liver (10) 10
recombinant proteins (10) 10
rna (10) 10
abridged index medicus (9) 9
adenine - analogs & derivatives (9) 9
alanine transaminase - blood (9) 9
association (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1997, Health co-operation papers, Volume n. 15, 252
Book
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2004, Volume 351, Issue 5, pp. 438 - 450
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 5/2011, Volume 52, Issue 9, pp. 1164 - 1173
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 141, Issue 3, pp. 881 - 889.e1
Background & Aims We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in... 
Gastroenterology and Hepatology | Clinical Trial | Liver Disease | C209 | VX-950 | VX-951 | THERAPY | HEPATITIS-C VIRUS | COMBINATION | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Single-Blind Method | Hepatitis C, Chronic - metabolism | Interferon-alpha - pharmacology | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | RNA, Viral - genetics | Adult | Female | Drug Therapy, Combination | Polyethylene Glycols - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Recombinant Proteins - pharmacology | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Hepatitis C, Chronic - genetics | Oligopeptides - pharmacology | RNA, Viral - drug effects | Ribavirin - pharmacology | Evaluation | Complications and side effects | Care and treatment | RNA | Interferon | Genetic aspects | Hepatitis C | Hepatitis C virus | Consulting services | Ribavirin
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2009, Volume 53, Issue 10, pp. 4264 - 4269
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2013, Volume 56, Issue 2, pp. 209 - 217
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 11, p. e13540
Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in... 
INFECTED INDIVIDUALS | KAPOSIS-SARCOMA | HLA-DR | CELLULAR RESERVOIRS | ACTIVE ANTIRETROVIRAL THERAPY | CLINICAL-TRIALS | BIOLOGY | GENE-EXPRESSION | CYNOMOLGUS MONKEYS | PERIPHERAL-BLOOD | HUMAN-IMMUNODEFICIENCY-VIRUS | T-Lymphocytes, Regulatory - metabolism | Prospective Studies | Humans | Middle Aged | AIDS Vaccines - immunology | Male | T-Lymphocytes, Regulatory - immunology | CD4-Positive T-Lymphocytes - immunology | HIV Infections - immunology | Killer Cells, Natural - immunology | Adult | Female | tat Gene Products, Human Immunodeficiency Virus - immunology | HIV-1 - metabolism | Immunization - adverse effects | Immunization - methods | Lymphocyte Activation | HIV Infections - virology | Homeostasis - immunology | Treatment Outcome | Combined Modality Therapy | Antiretroviral Therapy, Highly Active | HIV-1 - immunology | B-Lymphocytes - immunology | Nausea - etiology | Asthenia - etiology | HIV Infections - therapy | Aged | CD8-Positive T-Lymphocytes - immunology | Antiviral agents | Immunization | Genes | Development and progression | Hostages | Disease susceptibility | HIV (Viruses) | Gene expression | Infection | Proteins | Highly active antiretroviral therapy | Lymphocytes | Analysis | Health aspects | Laboratories | CD8 antigen | Homeostasis | Viruses | Lymphocytes T | Activation | Macrophages | Cell activation | Reduction | Immunology | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | CD38 antigen | Human immunodeficiency virus--HIV | Physiology | Telomerase | Immune system | Antigens | Immunological memory | Memory cells | Immune response | Immunoregulation | Dermatology | Glycoproteins | Virology | CD4 antigen | Tat protein | Monocytes | Infectious diseases | Lymphocytes B | Stem cells | Replication | Histocompatibility antigen HLA | Regulatory proteins | Apoptosis | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article